If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the numbers actually say about the stock. Pfizer's recent share price reflects ...

Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...

Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than ...

Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn more about PFE stock here.